Our rapidly growing knowledge about cancer genetics attests to the widespread occurrence of alterations at genes encoding different components of the SWI/SNF complex. This reveals an important new feature that sustains cancer development: the blockade of chromatin remodeling. Here, we provide an overview of our current knowledge on the gene alterations of chromatin-remodeling factors, and how they relate to cancer and human developmental diseases. We also consider the functional repercussions, particularly how the inactivation of the SWI/SNF complex impairs the appropriate cell response to nuclear receptor signaling, which, in turn, prevents cell differentiation and sustains cell growth independently of the environment.
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Two SWI/SNF multiprotein complexes have been described in mammals, the BRG1-associated factors (BAF), also called SWI/SNF-a, and the polybromo-BRG1-associated factors, also known as SWI/SNF-b. The complexes share a number of proteins, such as BAF170, BAF155, BAF60a/b/c, BAF57, BAF53a/b, BAF47, BAF45a/b/c/d and b-actin, while differing with respect to other components. 4, 5 For example, the a-complex includes the associated members BAF250a and BAF250b, which are interchangeable and not present simultaneously in the complex. 4, 5 By contrast, the b-complex contains up to three additional members: the BAF180, BAF200 and BRD7 proteins. 4, 5 However, the main difference between the SWI/SNF complexes is the ATPase. Although this can be either BRG1 or BRM in the SWI/SNF-a, it is only BRG1 in the SWI/SNF-b.
Although the focus of this review is the SWI/SNF complex, it should be borne in mind that the picture is greatly complicated by the participation of BRG1 and other SWI/SNF components in epigenetic complexes other than the SWI/SNF. Among these are the chromatin-remodeling complexes WINAC and NUMAC, and the epigenetic transcriptional repressor complexes NcoR and mSin3A/HDAC. 2 
GENE ALTERATIONS IN COMPONENTS OF CHROMATIN-REMODELING COMPLEXES ARE COMMON IN HUMAN CANCER
More than 10 years have passed since inactivating mutations at SMARCB1 (henceforth SNF5) were first reported in human cancer, linking chromatin remodeling and cancer development. 6 As a bona fide tumor-suppressor gene, SNF5 is biallelically inactivated in human tumors. Most mutations predict truncated proteins and are mainly found in malignant rhabdoid tumors (MRTs), a pediatric and highly lethal form of cancer that arises primarily in kidney and brain. SNF5 inactivation can also be found in choroid plexus carcinomas and in rare cases of pediatric brain tumors. 7 The mutations arise either somatically or in the germ line conferring, in the latter case, a cancer predisposition syndrome. 6 Alongside SNF5, mutations in SMARCA4 (henceforth BRG1) were identified a few years later in different types of cancer cell line 8, 9 and in lung primary tumors 10, 11 ( Figure 1 ). In a screening of lung cancer cell lines, BRG1 inactivation was found to affect more than a quarter of non-small cell lung cancer lines. This is the fourth most commonly altered gene in this type of lung cancer after TP53, CDKN2A and LKB1. 12 In 2006, Kiskinis et al. 13 reported the presence of an inactivating mutation in another core member of the SWI/SNF complex, the SMARCE1 (encoding the BAF57 protein), in a breast cancer cell line, and, 2 years later, inactivation at PBRM1 (encoding the BAF180) was also detected in breast cancer. ovarian and kidney malignancies, respectively, are mainly found in clear cell carcinomas. This evidences a specific clustering of the alterations at these two components of the SWI/SNF complex in histopathological subtypes. Furthermore, these technologies have revealed that other components of chromatin-remodeling complexes, or factors closely related to them, are mutated in cancer, such as ARID1B (encoding BAF250b) and ARID2 (encoding BAF200) (Figure 1 ). The list continues to grow and Figure 1 provides a summary of the SWI/SNF-related proteins that are known to be genetically inactivated in human cancer, updating that of a previous review. 5 It has to be taken into account that the evidences of genetic inactivation in genes encoding chromatinremodeling factors are recent and that most data comes from deep sequencing technologies applied to whole genome or to exomes, a type of approach that lead to a certain amount of false negative results. Therefore, efforts in individual sequencing of each gene, combined with approaches to accurately detect intragenic homozygous deletions in tumor-suppressor genes, are required to definitely determine the precise frequency of alterations at these genes, in the distinct types of tumors.
In addition to mutations in genes coding for proteins of the SWI/SNF complex, mutations of components of other chromatin-remodeling complexes or of factors controlling chromatin marks, such as EP300 or CREBBP, have been found in cancer. 19, 20 However, this specific subject is not covered in the present review.
PHENOTYPES ASSOCIATED WITH GERM-LINE ALTERATIONS AT CHROMATIN REMODELERS: HUMAN SYNDROMES AND MOUSE MODELS
Most known tumor-suppressor genes are associated with cancerrelated syndromes. These syndromes are caused by a germ-line mutation, either inherited or arising de novo, in one of the two alleles of the tumor-suppressor gene and conferring a predisposition to develop cancer. Intriguingly, in the case of chromatin-remodeling components, in addition to cancer predisposition, germ-line mutations at some of these genes cause developmental autism-related diseases.
Germ-line mutations in SWI/SNF components and cancer predisposition A strong indicator of the participation of chromatin-remodeling complexes in cancer development is their association with a predisposition to develop cancer in the form of cancer-related syndromes, in humans, and in mouse genetic models. In this regard, the SNF5 gene is biallelically inactivated in MRTs somatically and in the germ line, causing the so-called rhabdoid predisposition syndrome. 7 Individuals with this syndrome are predisposed to having renal or extrarenal MRTs, and a variety of tumors of the central nervous system, including choroid plexus carcinoma, medulloblastoma and central primitive neuroectodermal tumors (Table 1) . Furthermore, germ-line mutations at SNF5 are associated with schwannomatosis, a rare hereditary cancer syndrome in which patients develop multiple non-vestibular schwannomas, and with the development of multiple meningiomas. 21, 22 Regardless of whether the mutations at SNF5 in the MRTs, schwannomas or meningiomas arise somatically or already exist in the germ line, the second allele is also altered by loss of heterozygosity, which is consistent with the two-hit recessive model of oncogenesis. Moreover, the genetic mouse models support the implication of SNF5 in cancer development. 23 Homozygous knockout mice for Snf5 experience embryonic lethality and, similarly to what happens in humans, heterozygous mice are born and appear normal. However, at 5 weeks of age, these mice start developing tumors that look similar to human MRTs, frequently developing metastases in the lungs and lymph nodes. 23 On the other hand, the relationship of inactivating mutations at BRG1 with human cancer predisposition is not well established. One publication has reported a BRG1 germ-line nonsense mutation associated with the predisposition to developing MRTs, 24 the same cancer syndrome as that associated with SNF5 mutations. Consistent with the BRG1 cancer-related syndrome, Brg1 þ / À mice have an increased risk of developing cancer (Table 1) . However, in contrast to the MRT syndrome, Brg1 þ / À mice are prone to developing epithelial tumors at different locations, such as the neck and the groin, which display different features of epitheloid origin. 25, 26 Complementary to these data, lung Brg1-targeted heterozygous mice also develop tumors in response to carcinogens. 27 Other tissue-specific knockout mouse models for Brg1 have been generated that trigger specific effects. 28 Some of these models are discussed below.
In contrast to Brg1 and Snf5, Brm knockout mice are viable and do not have an increased risk of developing tumors. 29 These observations, coupled with the lack of BRM (also called SMARCA2) mutations in tumors of sporadic origin, might imply that BRM has no role in cancer. However, a complete loss of BRM expression has been reported in some tumors, 4 which suggests that additional studies are required to rule out definitively the participation of BRM in cancer development.
Germ-line mutations at SWI/SNF and autism-related disorders Recently, germ-line mutations at several of the components of the SWI/SNF chromatin-remodeling complex have also been linked to human syndromes across the spectrum of autism disorders. In particular, with the autosomal dominant syndromes NicolaidesBaraitser and Coffin-Siris, which are very rare diseases (o100 cases of each, worldwide) and show several common clinical characteristics, including multiple congenital malformations, microcephaly and intellectual disability. [30] [31] [32] [33] [34] Figure 2 summarizes the various mutations found in these syndromes and their location, distributed into the different domains of the proteins. It is still unclear how germ-line mutations at these genes can give rise to either a cancer predisposition syndrome or a developmentally related syndrome, which are disorders of distinct nature. In this regard, it is worth mentioning that, in contrast to what happens in cancer, the mutations in BRG1 and SNF5 in individuals with the developmental syndromes were non-truncating (either missense changes or in-frame deletions), implying that they exert gain-of-function or dominant-negative effects. 32 Conversely, the patterns of alterations at the ARID1A and ARID1B genes, typically mutations that predict truncated proteins, are very similar in the two types of disease. The reasons for this are not yet clear and merit intensive investigation. In spite of this, there are some Abbreviations: BAF, BRG1-associated factors; ND, not determined.
The SWI/SNF genetic blockade OA Romero and M Sanchez-Cespedes identical mutations that have been found both in cancer and in the developmental syndromes ( Figure 2) . Despite all the uncertainties, it is worth mentioning that alterations in the brain are related features in these diseases. For example, the main clinical observations in individuals with the Nicolaides-Baraitser and Coffin-Siris syndromes are microcephaly and severe intellectual disability. In this regard, a small percentage of the Brg1 þ / À and Smarcc1 þ / À mice are born with dire neurological abnormalities such as exencephaly, a condition where the brain is located outside of the skull, due to an abnormal closure of the neural tube (Table 1 ). In addition, among the types of cancer suffered by individuals that inherit an SNF5 mutation are a variety of tumors of the central nervous system. 21, 22 Altogether, these observations highlight the importance of an intact SWI/SNF complex for correct development and brain homeostasis.
Finally, it is worth pointing out that, similar to what happens with the SWI/SNF complex, alterations at genes involved in other chromatin-remodeling complexes have also been linked to developmentally related disorders, involving intellectual disability such as the alpha thalassemia/ mental retardation X-linked and the Floating Harbor syndromes, which are due to germ-line mutations at ATRX and SRCAP, respectively. 35, 36 INVOLVEMENT OF THE SWI/SNF COMPLEX IN CELL DIFFERENTIATION The SWI/SNF complex regulates transcription through its ability to remodel chromatin. Despite having no intrinsic ability to bind DNA, the SWI/SNF complex is commonly recruited to gene promoters by transcription factors. Once there, the complex remodels the chromatin structure by the ATP-dependent disruption of DNA-histone interactions at the nucleosomes to activate/ repress gene expression. 37 In this way, the complex acts as a transcriptional regulator of large sets of genes involved in multiple developmental pathways, including early embryonic development and tissue specification. 37 Moreover, the SWI/SNF complex containing BRG1 has been shown to participate in the reprogramming of somatic cells. 38 The SWI/SNF complex is involved in the differentiation of a variety of mammalian tissues, for example, adipocytes, erythropoietic cells, hematopoietic cells, hepatocytes, neurons, osteoblasts and skeletal muscle, among others.
25,39-44 BRG1 has been the best studied SWI/SNF component in this regard, and the requirement of BRG1 for the appropriate differentiation of most mammal tissues is well known. 37 In this regard, the tissue-specific knockout mice models for Brg1 provide with important information about the role of Brg1 in cell differentiation. 28 For example, a Brg1 deletion in the endocardium lead to embryonic lethality due to impaired ventricular trabeculation during cardiogenesis. 25 Similarly, brain-specific deletions of Brg1 cause defects in neural stem/progenitor cell maintenance, impaired gliogenesis and defects in brain development (exencephaly). Furthermore, the conditional deletion of Brg1 in developing hematopoietic and endothelial cells leads to abnormalities in erythropoiesis, 44 and the Brg1 deletion in the thymus has as a consequence a dramatic reduction in total thymocyte cellularity and specially in CD4 þ CD8 À or CD4 À CD8 þ cells. 43 The involvement of the SNF5 component in tissue differentiation is also well established and the abrogation of SNF5 expression by RNA interference is known to prevent neural differentiation in the presence of nerve growth factor. 45 SNF5 is also essential for hepatocyte and adipocyte differentiation. 41, 46 Furthermore, BAF60c has been implicated in the differentiation of muscle/ heart and retina, [47] [48] [49] and in the insulin-induced lipogenic gene activation in the liver, 50 whereas BAF200 is essential for osteoblast differentiation. 51 The participation of other components of the SWI/SNF complex in tissue-specification processes is not well understood.
The role of the SWI/SNF complex in cell differentiation and tissue-specification relates to its dynamic DNA specificity and, therefore, the ability to control specific gene expression programs, depending on the physiological environment of the cell. The control over the cell environment exerted by SWI/SNF is related to its critical regulation of nuclear receptor hormone-responsive promoters. Studies suggest that nuclear receptors recruit SWI/SNF activity to gene-specific promoters, in a ligand-dependent manner, by which SWI/SNF functions to remodel the chromatin architecture. Components of the SWI/SNF complex bind to various nuclear receptors, for example, estrogen receptor, progesterone receptor, androgen receptor, glucocorticoid receptor (GR), retinoic acid receptor (RAR), peroxisome proliferator-activated receptor gamma (PPARg) and vitamin D3 receptor, among others, to change gene expression programs, accordingly. [52] [53] [54] [55] [56] For example, it is known that upon exposure to glucocorticoids (GCs), GR undergoes a structural conformational change that drives translocation from the cytoplasm to the nucleus, where it binds the chromatin remodelers, including the SWI/SNF complex, to modify gene expression. 57 Adipocyte differentiation requires the cooperation between various nuclear receptors, including GR, retinoid X receptor and PPARg, in addition to chromatin remodeling. 58 Cell metabolism is another process controlled by the interaction of nuclear receptor with the SWI/SNF complex. In this regard, the PPARg interacts with the SWI/SNF complex, 54 to regulate adipogenesis, lipid metabolism and glucose homeostasis, and the induction of the PPARg nuclear hormone receptor during adipogenesis requires SWI/SNF enzymes. 59, 60 In spite of all this knowledge, our understanding of the specific gene targets that are regulated by BRG1 and the SWI/SNF complex in each physiological atmosphere is still limited. The use of chromatin immunoprecipitation combined with transcriptome analysis has revealed some of the targets of SWI/SNF activity, although the information is still fragmentary and incomplete. [61] [62] [63] 
CHROMATIN-REMODELING BLOCKADE AND HORMONE REFRACTORINESS IN CANCER CELLS: EFFECTS ON CANCER THERAPEUTICS
We recently demonstrated that restoration of BRG1 activity in lung cancer cells leads, at least to some extent, to the restitution of the normal lung gene expression signature. 64 Conversely, it has been shown that the loss of SNF5 increases the expression of the polycomb gene EZH2, triggering the activation of stem-associated programs. 65 These observations indicate that abrogation of the SWI/SNF complex activity enables the cancer cell to maintain undifferentiated gene expression programs. Overall, this is consistent with the role of the SWI/SNF complex in cell differentiation and tissue specification.
It is very likely that the maintenance of stem-associated programs of gene expression, acquired by the cancer cell through the inactivation of the SWI/SNF complex, is related to the impaired ability of the cell to respond to nuclear receptor signaling. Retinoic acid (RA) is one of the essential compounds controlling embryonic development and tissue specification. It acts on progenitor cell populations to ensure the correct development of almost every embryonic tissue, including lung, pancreas, thyroid, parathyroid, thymus, specific cardiac population and several neural structures. 66 Several observations have established a connection between a deficient response to RA and GCs with cancer. For example, it is well known that many cancer cells have lost the capability of responding to nuclear receptor signaling, despite expressing nuclear receptors. 67 Furthermore, RA deficiency promotes the generation of lung tumors in mice, 68 whereas a failure to respond to GCs, is a risk factor for lung cancer, especially in smokers. 69 Moreover, it has recently been demonstrated that BRG1 inactivation in lung, breast and prostate cancer cells conferred acquired refractoriness to RA and GC receptor signaling, whereas re-expression of BRG1 restored sensitivity. 64 The involvement of BRG1 and the SWI/SNF complex in mediating the action of the RA and GCs is also therapeutically important. GCs have anti-inflammatory properties and are widely used to treat inflammatory conditions and some types of cancer. 69 For example, GCs are used in the curative treatment of acute lymphoblastic leukemia. Resistance to GCs, which is an important adverse prognostic factor in newly diagnosed acute lymphoblastic leukemia patients, is associated with a lower level of expression of genes for core subunits of the SWI/SNF complex, that is, BRG1, ARID1A and SNF5. 70 RA is also used in cancer treatment, specifically in some neuroblastomas and in acute promyelocytic leukemia. The latter is characterized by enduring the promyelocytic leukemia-RARa gene fusion that has a critical role in its genesis and that is the target of retinoid therapy. 71 In neuroblastoma cells, we demonstrated that the depletion of BRG1, with the use of small interference RNA, reverted the capability of the cells to respond to treatment with RA. 64 Further, it is well established that breast and ovarian cancer are often resistant to treatments with estrogen antagonists and that some prostate cancers are refractory to antiandrogen-based therapies. As inactivation at BRG1, SMARCC1 or ARID1A, among others, are present in breast, ovarian and prostate cancer (Table 1) , it is reasonable to hypothesize that the resistance to these hormonebased treatments is due to a malfunction of the SWI/SNF complex. In support of this, it is known that the response to cancer cells of estrogen receptor, progesterone receptor or androgen receptor requires an intact SWI/SNF complex. [72] [73] [74] Although the role of the SWI/SNF complex in controlling cell differentiation is well known, it may not be the only mechanism by which its inactivation contributes to carcinogenesis. In this regard, the SWI/SNF complex is involved in other cell processes such as in early embryonic development, in DNA repair, in cell migration and in cell cycle. Some of these proceses are related to important functional pathways that are considered to have important roles in the genesis and the development of cancer in humans, including the Hedgehog-Gli, interferon-:signaling, the ROCK1-RHOA transduction pathway, retinoblastoma, among others. 5, 75, 76 The relationship of SWI/SNF with some of these functions may be through direct physical interactions, such as RB, LKB1, GLI, bCATENIN, SMADs, BRCA1 and CFOS, among others, 28 The SWI/SNF genetic blockade OA Romero and M Sanchez-Cespedes and through the transcriptional regulation, by the SWI/SNF complex, of proteins involved in these processes. 61, 63 THE BRG1 AND MYC FUNCTIONAL CONNECTION Cancer genes encoding proteins that have equivalent biological function for cancer growth tend not to be simultaneously altered in the same tumor specimen. This hypothesis is borne out by the examples of the cell-cycle components RB and CDKN2A, and of the receptor/signal transducer EGFR and KRAS, which are among the best established genes behaving with a pattern of mutually exclusive mutations in lung cancer. 12 Therefore, identifying the genetic relationships between cancer genes may provide hints about the biological function of the encoded protein in cancer development.
Using lung cancer cell lines, we searched for genes that were altered only in BRG1 wild-type tumors and found that amplification at any MYC-family members was mutually exclusive to BRG1 inactivation, 9 suggesting a functional relationship between the SWI/SNF complex and MYC. In agreement with this, a strong inverse correlation was found between the expression profiles of the lungs of mice expressing tissue-specific activated Myc and that of lung cancer cell lines after restoring BRG1 activity. 64 Additional observations that support the functional connection are that BRG1 is recruited to the E-boxes, the MYC consensus region in the DNA, and that the complex is required to mediate gene transactivation of MYC target genes. 64, 77 Moreover, recruitment of SWI/SNF to MYC-binding promoters is also dependent on the MYC-INI1 interaction. 78 Overall, these observations strongly suggest that the tumor-suppressor role of BRG1 and of the SWI/SNF complex involve, among other factors, the control of MYC activity. Thus, for the cancer cell, enduring oncogenic activation at any of the MYC family of genes is, to some extent, functionally tantamount to inactivate the SWI/SNF complex. In spite of the functional equivalence for cancer development, carrying either MYC activation or SWI/SNF-complex inactivation probably implies some different capabilities for the cancer cell. For example, we reported that while lung cancer cells carrying inactivation of BRG1 were completely refractory to RA or GC treatment, the cells with MYC amplification indicated a moderate response, measured as the ability to increase the expression of target genes. 64 Further, a partial reduction in cell growth was observed after RA treatment in lung cancer cell lines carrying MYC amplification. 79 Figure 3 illustrates these characteristics.
Finally, it is important to consider the potential use of this knowledge in cancer therapeutics. Although the therapies based on RA or GC are not currently of use for treating most solid tumors, perhaps in combination with other drugs, they could be used to treat cancers carrying amplified MYC. However, our current understanding of SWI/SNF biology suggests that tumors with inactivation of BRG1, and possibly of other components of the SWI/SNF complex, will be intrinsically resistant. On the other hand, as an oncogene, the MYC protein is potentially 'druggable' and, in this regard, different researchers are investing efforts into developing compounds that inhibit the activity of MYC. Should anti-MYC drugs become available, it will be important to select tumors that are likely to respond to treatment with them. Although MYC-amplified tumors are likely to be sensitive, it is difficult to predict whether tumors with genetically inactivated components of the SWI/SNF complex will respond to these therapies.
FUTURE PERSPECTIVES
Gene alterations that abrogate the activity of several chromatinremodeling factors, especially those of the SWI/SNF complex, are emerging as widespread phenomena in cancer. In as much as an abnormal chromatin-remodeling function is expected to be critical for cancer development, attempts to elucidate their biological repercussions are needed before our knowledge can influence clinical management. Of special interest is the involvement of the SWI/SNF complex in mediating the activity of vitamins, hormones and factors that control the cell differentiation processes. The presence of the inactivating mutations of genes encoding components of the SWI/SNF complex may provide an explanation for refractoriness to treatment based on the compounds that are therapeutically used in some types of leukemias, neuroblastomas and hormone-related tumors such as breast, ovarian and prostate cancer. This possibility should be explored in depth. It is also important to understand the functional relationship of the chromatin-remodeling complexes with other well-known cancer proteins such as the MYC oncogenes, and to look into the potential use of these observations in cancer therapeutics.
